Paridaens R
Department of Oncology, U.Z. Gasthuisberg, Leuven, Belgium.
Semin Oncol. 1998 Oct;25(5 Suppl 12):3-6.
The anthracyclines are among the most active agents in the treatment of breast cancer. In recent years, the taxoids have produced promising results as single agents in breast cancer. Average overall response rates of 43% in previously untreated and 29% in pretreated metastatic breast cancer have been reported in phase II trials with paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ). Based on the known activity of doxorubicin and the single-agent phase II results of paclitaxel, two phase III randomized trials comparing these drugs as monotherapy in first-line, with crossover on progression, were conducted by the European Organization for Research and Treatment of Cancer and the Intergroup. The preliminary results of these studies were presented at international congresses and will be discussed here.
蒽环类药物是治疗乳腺癌最有效的药物之一。近年来，紫杉烷类药物作为单一药物治疗乳腺癌已取得了令人鼓舞的结果。在紫杉醇（泰素；百时美施贵宝公司，新泽西州普林斯顿）的II期试验中，报道了未经治疗的转移性乳腺癌的平均总缓解率为43%，先前接受过治疗的为29%。基于阿霉素已知的活性以及紫杉醇单一药物II期试验的结果，欧洲癌症研究与治疗组织和国际协作组进行了两项III期随机试验，比较这些药物作为一线单一疗法的疗效，并在疾病进展时进行交叉治疗。这些研究的初步结果已在国际大会上公布，并将在此进行讨论。
